Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo‐controlled trial
C. Lai, C. Ching, A. K. Tung, E. Li, J. Young, A. Hill, B. C. Wong, J. Dent, P. Wu – 30 December 2003 – Lamivudine is a novel 2′,3′‐dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo. We performed a single‐blind, placebo‐controlled study to assess its effectiveness and safety in Chinese hepatitis B surface antigen (HBsAg) carriers. Forty‐two Chinese HBsAg carriers were randomized to receive placebo (6 patients) or lamivudine orally in dosages of 25 mg, 100 mg, or 300 mg daily (12 patients for each dosage).